An Outlook On Druggable Targets To Combat Pancreatic Ductaladenocarcinoma

Pancreatic ductal adenocarcinoma (PDAC) is due to uncontrolled proliferations of exocrine cells in the ducts of pancreas and it is a 'silent cancer' as the PDAC does not signal for any apparent symptoms until its stage IV. The PDAC alone accounts about 95% of pancreatic cancers and 99% of people with stage IV PDAC have been reported to survive less than 5 years. In this review article, comprehensive inhibition of certain proteins playing essential roles in the Ras-mediated signal transduction pathway and autophagy has been hypothesized as an attractive strategy to combat the PDAC. Rationale for the hypothesis and possible druggable targets in the above said biological process has been discussed in detail.